Campbell Newman Asset Management Inc. Reduces Stock Holdings in Stryker Corporation $SYK

Campbell Newman Asset Management Inc. lowered its stake in shares of Stryker Corporation (NYSE:SYK) by 5.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 59,656 shares of the medical technology company’s stock after selling 3,218 shares during the quarter. Stryker makes up about 1.4% of Campbell Newman Asset Management Inc.’s holdings, making the stock its 27th biggest position. Campbell Newman Asset Management Inc.’s holdings in Stryker were worth $18,782,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of SYK. State Street Corp increased its position in shares of Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after purchasing an additional 311,507 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Stryker by 0.6% in the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock valued at $2,571,357,000 after purchasing an additional 45,478 shares during the period. Geode Capital Management LLC boosted its position in shares of Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after purchasing an additional 69,851 shares during the period. Norges Bank purchased a new position in Stryker during the 4th quarter worth approximately $1,822,272,000. Finally, Bank of America Corp DE acquired a new position in Stryker during the second quarter worth approximately $1,404,284,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other Stryker news, insider Dylan Bram Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by company insiders.

Stryker Price Performance

Shares of SYK opened at $331.32 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The stock’s 50 day moving average is $329.10 and its two-hundred day moving average is $331.47. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The firm has a market capitalization of $127.08 billion, a PE ratio of 34.33, a P/E/G ratio of 2.05 and a beta of 0.76.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period last year, the firm earned $3.13 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on SYK shares. Evercore set a $350.00 price objective on Stryker in a report on Monday, July 6th. Royal Bank Of Canada cut their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Citigroup reiterated a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. Wells Fargo & Company lowered their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Finally, BMO Capital Markets assumed coverage on shares of Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.